ssflxl
![]()
Posts:204
Dear Drs
here's the Yahoo article about LDK 378.
http://news.yahoo.com/novartis-says-lung-cancer-patients-respond-drug-s…
It is unclear to me if this agent only worked for those with ALK mutation or all those with NSCLC. From the article (not scientific), it sounds like it has a positive impact on all NSCLC
thanks
ssflxl
Forums
Reply # - March 28, 2014, 05:24 AM
Reply To: LDK 378
Hi ssflxl,
It looks like the data that was just reported by Novartis and referenced in that Yahoo story was based on a study of 114 patients with ALK positive NSCLC: http://www.fiercebiotech.com/press-releases/novartis-study-published-ne…
JimC
Forum moderator
Reply # - March 28, 2014, 06:22 PM
Reply To: LDK 378
Yes, it's very good news, but it's not really new information that ceritinib, or LDK378, has very significant activity against ALK-positive advanced NSCLC. Because it is an ALK inhibitor, there is far greater interest in its activity in the minority of patients with ALK-positive NSCLC than in a broad, molecularly unselected population. In fact, there is a growing movement (coming from such major groups as ASCO) to stop doing any trials of targeted therapies in molecularly unselected patients.
-Dr. West
Reply # - March 28, 2014, 06:22 PM
Reply To: LDK 378
Yes, it's very good news, but it's not really new information that ceritinib, or LDK378, has very significant activity against ALK-positive advanced NSCLC. Because it is an ALK inhibitor, there is far greater interest in its activity in the minority of patients with ALK-positive NSCLC than in a broad, molecularly unselected population. In fact, there is a growing movement (coming from such major groups as ASCO) to stop doing any trials of targeted therapies in molecularly unselected patients.
-Dr. West